# AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer

> **NCT00427973** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 17 (actual)

## Conditions studied

- Adult Primary Hepatocellular Carcinoma
- Advanced Adult Primary Liver Cancer
- Localized Unresectable Adult Primary Liver Cancer
- Recurrent Adult Primary Liver Cancer

## Interventions

- **DRUG:** cediranib maleate
- **OTHER:** laboratory biomarker analysis
- **PROCEDURE:** computed tomography
- **PROCEDURE:** dynamic contrast-enhanced magnetic resonance imaging
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00427973
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-05
- **Primary completion:** 2010-04
- **Final completion:** 2012-03
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** The study was stopped prior to 2nd stage.
- **Last updated:** 2016-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00427973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00427973, "AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00427973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*